- Conditions
- Carcinoma, Non-small-Cell Lung
- Interventions
- Amivantamab, Lazertinib, Carboplatin, Pemetrexed, Direct Oral Anticoagulant (DOAC), Low Molecular Weight Heparin (LMWH)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 26
- States / cities
- La Jolla, California • Orange, California • Stanford, California + 21 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 30
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hemorrhage, Surgical, Hemorrhage Postoperative, Blood Loss, Surgical, Blood Loss, Postoperative
- Interventions
- Sham comparator, DrugSorb-ATR system
- Device
- Lead sponsor
- CytoSorbents, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 27
- States / cities
- Sacramento, California • Denver, Colorado • New Haven, Connecticut + 22 more
- Conditions
- Venous Thromboembolic Disease, Pulmonary Embolism and Thrombosis, Deep Vein Thrombosis, Hospitalism
- Interventions
- EHR (electronic health record) alert, No EHR (electronic health record) alert
- Other
- Lead sponsor
- Scott C. Woller, MD
- Other
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 152,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Murray, Utah
- Conditions
- Atrial Fibrillation, Stroke, Bleeding
- Interventions
- Antiplatelet-only strategy, Oral Anticoagulant plus background antiplatelet therapy
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 51
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Stanford, California + 40 more
- Conditions
- Intracerebral Hemorrhage, Intracerebral Haemorrhage, Intraventricular Hemorrhage, Stroke, Cerebrovascular Disease
- Interventions
- Reversal of Oral anticoagulation within 30 minutes, Early intensive blood pressure lowering, Treatment of pyrexia, Hyperglycemia treatment, Do-not-resuscitate (DNR) or withdrawal of care, Referral to Intensive Care, Referral to Neurosurgery, Repeat brain imaging, Standard care
- Other · Diagnostic Test
- Lead sponsor
- Region Skane
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Cardiovascular Diseases, Venous Thromboembolism, Atrial Fibrillation, Bleeding, Stroke
- Interventions
- Clinical Pharmacist Intervention
- Other
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 561 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Cancer, VTE (Venous Thromboembolism)
- Interventions
- Apixaban 2.5 mg twice daily, Apixaban 5 mg once daily, No anticoagulation
- Drug
- Lead sponsor
- University of Vermont
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 996 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- Uterine Hemorrhage
- Interventions
- Direct oral anticoagulant (DOACs), Warfarin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 961,985 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Titusville, New Jersey
- Conditions
- Pulmonary Embolism, Venous Thromboembolism, Atrial Fibrillation
- Interventions
- New-prescription Alert, New-prescription Alert with referral option, Existing-prescription notification to prescriber, Existing-prescription notification to pharmacist
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- Not listed
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Blood Clot
- Interventions
- Rivaroxaban, Apixaban, Edoxaban, Dabigatran, Warfarin, Dalteparin, Enoxaparin, Fondaparinux
- Drug
- Lead sponsor
- Alliance Foundation Trials, LLC.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 811 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 151
- States / cities
- Chula Vista, California • Fremont, California • Fresno, California + 104 more
- Conditions
- Coagulation
- Interventions
- Whole Blood Clotting Time
- Device
- Lead sponsor
- Perosphere Technologies Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Danbury, Connecticut • Rockville, Maryland • Denville, New Jersey + 1 more
- Conditions
- DOAC Eligible Subjects
- Interventions
- TEG6s DOAC Cartridge
- Device
- Lead sponsor
- Haemonetics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 385 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 4
- States / cities
- South Bend, Indiana • Duluth, Minnesota • Spartanburg, South Carolina + 1 more
- Conditions
- Atrial Fibrillation, Ischemic Stroke, Acute
- Interventions
- Left Atrial Appendage Occlusion
- Other
- Lead sponsor
- Kansas City Heart Rhythm Research Foundation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Hypercoagulable States
- Interventions
- Observational
- Other
- Lead sponsor
- Methodist Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Drug-Related Side Effects and Adverse Reactions
- Interventions
- Not listed
- Lead sponsor
- Cipherome, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- San Jose, California
- Conditions
- Drug-Related Side Effects and Adverse Reactions, Treatment Failure
- Interventions
- Not listed
- Lead sponsor
- Cipherome, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Santa Clara, California
- Conditions
- Acute Myocardial Infarction
- Interventions
- Not listed
- Lead sponsor
- Methodist Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Treatment of Venous Thromboembolism in Cancer Patients, Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Low molecular weight heparin (LMWH), Direct Oral Anticoagulants (DOAC)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,708 participants
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Multiple Locations, Connecticut
- Conditions
- Venous Thrombosis, Neoplasms
- Interventions
- Heparin, Low-Molecular-Weight, or direct oral anticoagulants
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 3
- States / cities
- Minneapolis, Minnesota • Columbus, Ohio • Milwaukee, Wisconsin
- Conditions
- Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Spine Metastasis
- Interventions
- Apixaban
- Drug
- Lead sponsor
- James Bayley
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Pittburgh, Pennsylvania • Pittsburgh, Pennsylvania
- Conditions
- Splanchnic Vein Thrombosis, Cerebral Vein Thrombosis, Ovarian Vein Thrombosis, Renal Vein Thrombosis, Retinal Vein Thrombosis
- Interventions
- Direct Oral Anticoagulants
- Drug
- Lead sponsor
- University of Malta
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Myeloproliferative Neoplasm
- Interventions
- DOACs
- Drug
- Lead sponsor
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 442 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Acute Ischemic Stroke
- Interventions
- Intravenous tenecteplase (TNK), Placebo
- Drug
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 660 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2032
- U.S. locations
- 1
- States / cities
- Neptune City, New Jersey
- Conditions
- Atrial Fibrillation (AF)
- Interventions
- Not listed
- Lead sponsor
- McMaster University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 1,780 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 4
- States / cities
- Evanston, Illinois • Detroit, Michigan • Great Neck, New York + 1 more